COMMUNIQUÉS West-GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
23/04/2018
WAYNE, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
23/04/2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic candidates for the [...]
Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study
23/04/2018
The 5-year joint project was granted $2.5 million from the U.S. National Institutes of Health (NIH) Data from these studies will support BLA filing for marketing approval of PLX-R18 in the treatment of ARS HAIFA, Israel [...]
Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
23/04/2018
Trial being conducted in collaboration with Duke University NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies [...]
Annual Report 2017 Active Biotech AB (publ)
23/04/2018
PRESS RELEASE Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com . The Annual Report will only be digitally distributed. The English version will be available within short. Lund, [...]
Transactions under Novozymes’ stock buyback program
23/04/2018
Please read the full announcement in the attached PDF Attachment 2018_15_Stock_Buybackprogram_EN
Q Therapeutics Announces Joint Venture With REPROCELL
23/04/2018
PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATION SALT LAKE CITY andI YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, [...]
Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer
23/04/2018
BEDMINSTER, N.J., and DUBLIN, Ireland, April 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Share buy-back week 16/2018
23/04/2018
Announcement 23 April 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]
Notice of Annual General Meeting in Acarix AB
23/04/2018
Press release April 23, 2018 Notice of Annual General Meeting in Acarix AB The shareholders of Acarix AB, reg. no. 559009-0667, (the " Company "), are hereby convened to the annual general meeting to be held on [...]
Reminder: C-RAD Web Presentation Interim Report Q1 2018
23/04/2018
Presentation of the report for the first quarter of the fiscal year 2018: Date: Thursday April 26, 2018 / kl. 11:00 Venue: Online Presentation Topic: C-RAD Interim Report Q1 2018 Procedure: Please register online [...]
Acarix publishes the annual report for 2017
23/04/2018
Press release from Acarix AB (publ) 2018-04-23 Acarix publishes the annual report for 2017 Today, Monday April 23, Acarix is publishing its Annual Report for 2017 on the company website www.acarix.com . The Annual [...]
Shire plc : Rule 2.9 Announcement
23/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 23 April 2018 [...]
GENFIT : Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor
23/04/2018
GENFIT: Positive Outcome from the 24-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase 3 Clinical Trial with Elafibranor Safety data, including adverse events and laboratory data, were reviewed by the [...]
GENFIT : issue positive du DSMB suite à la revue planifiée à 24 mois des données de tolérance et de sécurité d'emploi d'elafibranor, dans l'étude clinique de Phase 3 RESOLVE-IT
23/04/2018
GENFIT : issue positive du DSMB suite à la revue planifiée à 24 mois des données de tolérance et de sécurité d'emploi d'elafibranor, dans l'étude clinique de Phase 3 RESOLVE-IT Les données de tolérance et de sécurité d' [...]
Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen
23/04/2018
CAMBRIDGE, Mass. and PARIS, April 23, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous system (CNS) diseases, [...]
Sensorion and Uconn Health Announce Identification of First Potential Biomarker for Noise-Induced Hearing Loss
23/04/2018
New study shows prestin in the blood following noise-induced trauma may be a biomarker for hearing loss MONTPELLIER, France, April 23, 2018 (GLOBE NEWSWIRE) -- New preclinical study findings presented at the 53 rd [...]
Sensorion’s SENS-401 Reduces Hearing Loss in Preclinical Study When Oral Administration Initiated Up to Four Days after Acoustic Trauma
23/04/2018
Key finding is that SENS-401 was effective even when time between acoustic trauma and treatment initiation reached up to four days MONTPELLIER, France, April 23, 2018 (GLOBE NEWSWIRE) -- Sensorion ( FR 0012596468: ALSEN [...]
Kiadis Pharma N.V notice of Annual General Meeting of shareholders
23/04/2018
Amsterdam, The Netherlands, April 23, 2017 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS ), a clinical stage biopharmaceutical company developing a T-cell immunotherapy [...]

Pages